TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026GuruFocus · 1 day ago
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential SymposiumGuruFocus · 2 days ago
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)GuruFocus · 4 days ago
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026GlobeNewsWire · 5 days ago
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026GuruFocus · Oct 17, 2026 Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.14 | -$0.12 | Beat |
| May 13, 2026 | -$0.25 | -$0.18 | Beat |
| Mar 5, 2026 | -$0.25 | -$0.27 | Miss |
| Nov 6, 2025 | -$0.29 | -$0.21 | Beat |
| Aug 12, 2025 | -$0.32 | -$0.27 | Beat |
| May 13, 2025 | -$0.35 | -$0.26 | Beat |